Tryptophan-Derived Uremic Toxins and Thrombosis in Chronic Kidney Disease
- PMID: 30322010
- PMCID: PMC6215213
- DOI: 10.3390/toxins10100412
Tryptophan-Derived Uremic Toxins and Thrombosis in Chronic Kidney Disease
Abstract
Patients with chronic kidney disease (CKD) display an elevated risk of thrombosis. Thrombosis occurs in cardiovascular events, such as venous thromboembolism, stroke, and acute coronary syndrome, and is a cause of hemodialysis vascular access dysfunction. CKD leads to the accumulation of uremic toxins, which exerts toxic effects on blood and the vessel wall. Some uremic toxins result from tryptophan metabolization in the gut through the indolic and the kynurenine pathways. An increasing number of studies are highlighting the link between such uremic toxins and thrombosis in CKD. In this review, we describe the thrombotic mechanisms induced by tryptophan-derived uremic toxins (TDUT). These mechanisms include an increase in plasma levels of procoagulant factors, induction of platelet hyperactivity, induction of endothelial dysfunction/ impairment of endothelial healing, decrease in nitric oxide (NO) bioavailability, and production of procoagulant microparticles. We focus on one important prothrombotic mechanism: The induction of tissue factor (TF), the initiator of the extrinsic pathway of the blood coagulation. This induction occurs via a new pathway, dependent on the transcription factor Aryl hydrocarbon receptor (AhR), the receptor of TDUT in cells. A better understanding of the prothrombotic mechanisms of uremic toxins could help to find novel therapeutic targets to prevent thrombosis in CKD.
Keywords: chronic kidney disease; thrombosis; tryptophan; uremic toxins.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures

Similar articles
-
The aryl hydrocarbon receptor-activating effect of uremic toxins from tryptophan metabolism: a new concept to understand cardiovascular complications of chronic kidney disease.Toxins (Basel). 2014 Mar 4;6(3):934-49. doi: 10.3390/toxins6030934. Toxins (Basel). 2014. PMID: 24599232 Free PMC article. Review.
-
Aryl Hydrocarbon Receptor Activation in Chronic Kidney Disease: Role of Uremic Toxins.Nephron. 2017;137(1):1-7. doi: 10.1159/000476074. Epub 2017 May 11. Nephron. 2017. PMID: 28490014 Review.
-
How do Uremic Toxins Affect the Endothelium?Toxins (Basel). 2020 Jun 20;12(6):412. doi: 10.3390/toxins12060412. Toxins (Basel). 2020. PMID: 32575762 Free PMC article. Review.
-
Thrombolome and Its Emerging Role in Chronic Kidney Diseases.Toxins (Basel). 2021 Mar 18;13(3):223. doi: 10.3390/toxins13030223. Toxins (Basel). 2021. PMID: 33803899 Free PMC article. Review.
-
Effects of Uremic Toxins from the Gut Microbiota on Bone: A Brief Look at Chronic Kidney Disease.Ther Apher Dial. 2015 Oct;19(5):436-40. doi: 10.1111/1744-9987.12307. Epub 2015 May 5. Ther Apher Dial. 2015. PMID: 25944654 Review.
Cited by
-
An Overview of Chronic Kidney Disease Pathophysiology: The Impact of Gut Dysbiosis and Oral Disease.Biomedicines. 2023 Nov 12;11(11):3033. doi: 10.3390/biomedicines11113033. Biomedicines. 2023. PMID: 38002033 Free PMC article. Review.
-
Myeloid cell-derived coagulation tissue factor is associated with renal tubular damage in mice fed an adenine diet.Sci Rep. 2021 Jun 9;11(1):12159. doi: 10.1038/s41598-021-91586-5. Sci Rep. 2021. PMID: 34108522 Free PMC article.
-
New insights into healthy ageing, inflammageing and frailty using metabolomics.Front Aging. 2024 Jul 9;5:1426436. doi: 10.3389/fragi.2024.1426436. eCollection 2024. Front Aging. 2024. PMID: 39044748 Free PMC article. Review.
-
Kynurenine pathway in kidney diseases.Pharmacol Rep. 2022 Feb;74(1):27-39. doi: 10.1007/s43440-021-00329-w. Epub 2021 Oct 6. Pharmacol Rep. 2022. PMID: 34617264 Free PMC article. Review.
-
Gut-derived uremic toxins and cardiovascular health in chronic kidney disease.Tzu Chi Med J. 2025 Apr 11;37(3):264-274. doi: 10.4103/tcmj.tcmj_293_24. eCollection 2025 Jul-Sep. Tzu Chi Med J. 2025. PMID: 40741605 Free PMC article. Review.
References
-
- Levin A., Stevens P., Bilous R.W., Coresh J., De Francisco A.L., De Jong P.E., Griffi K.E., Hemmelgarn B.R., Isek K., Lamb E.J., et al. KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Chapter 1: Definition and classification of CKD. Kidney Int. Suppl. 2013;3:19–62. doi: 10.1038/kisup.2012.64. - DOI
-
- Stevens P.E., Levin A. Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members Evaluation and management of chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline. Ann. Intern. Med. 2013;158:825–830. doi: 10.7326/0003-4819-158-11-201306040-00007. - DOI - PubMed
-
- Coresh J., Turin T.C., Matsushita K., Sang Y., Ballew S.H., Appel L.J., Arima H., Chadban S.J., Cirillo M., Djurdjev O., et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014;311:2518–2531. doi: 10.1001/jama.2014.6634. - DOI - PMC - PubMed
-
- Herzog C.A., Asinger R.W., Berger A.K., Charytan D.M., Díez J., Hart R.G., Eckardt K.-U., Kasiske B.L., McCullough P.A., Passman R.S., et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO) Kidney Int. 2011;80:572–586. doi: 10.1038/ki.2011.223. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous